Price
No data yet.
Social Signal Score
Analyst Ratings
19 analystsRevenue
$312.21M+76.65%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Randall A. Lipps
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- Employees
- 3,485
- Beta
- 0.98
- Country
- US
- Piotroski score
- 8 / 9 (Strong)
- Altman Z-score
- 2.53
Financials
Revenue
$312.21M+76.7%Net Income
$24.29M+1124.9%EBITDA
$13.83M-29.6%Free Cash Flow
$60.61M+13800.5%EPS (diluted)
$0.52+940.0%Shares Outstanding (diluted)
46.13M+24.4%Operating Expenses
$120.49MCash & Debt
$307.01MReturn of Capital
$388.0KRevenue by Segment (annual)
$1.18BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.18B | $2.05M | $0.04 |
| 2024 | $1.11B | $12.53M | $0.27 |
| 2023 | $1.15B | $-20.37M | $-0.45 |
| 2022 | $1.30B | $5.65M | $0.13 |
| 2021 | $1.13B | $77.85M | $1.79 |
| 2020 | $892.21M | $32.19M | $0.76 |
| 2019 | $897.03M | $61.34M | $1.48 |
| 2018 | $787.31M | $37.73M | $0.96 |
| 2017 | $716.16M | $20.61M | $0.81 |
| 2016 | $692.62M | $603.0K | $0.27 |
| 2015 | $484.56M | $30.76M | $0.86 |
| 2014 | $440.90M | $30.52M | $0.86 |
| 2013 | $380.58M | $23.98M | $0.69 |
| 2012 | $314.03M | $16.16M | $0.49 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from OMCL's reported EPS growth of -16.8% a year over 13 years. Historical EPS growth of -17% would project the company towards zero. Floored at -15% as a starting point.
- EPS in 5 years
- $0.02
- Implied price
- $0.36
- Return from $35.71
- -60.2% a year
To earn 15.0% a year on these assumptions you'd need to buy at $0.18 — -99.5% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 15 | 18 | 21 | 24 |
|---|---|---|---|---|---|
| -25.0% | -67.6% | -66.1% | -64.9% | -63.8% | -62.8% |
| -20.0% | -65.5% | -63.9% | -62.5% | -61.4% | -60.3% |
| -15.0% | -63.3% | -61.6% | -60.2% | -59.0% | -57.8% |
| -10.0% | -61.1% | -59.4% | -57.9% | -56.5% | -55.4% |
| -5.0% | -59.0% | -57.1% | -55.5% | -54.1% | -52.9% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (3)
- Newszacks.com·1d ago·Neutral
Is This the Right Time to Retain Omnicell Stock in Your Portfolio? OMCL raises its 2026 earnings outlook on cost discipline and efficiency, but rising memory costs and delayed Titan XT adoption pose challenges.
View source ↗ - Newszacks.com·62d ago·Positive
Omnicell Raises 2026 EPS Outlook as Memory Costs Pressure Margins OMCL raised its 2026 EPS outlook after a strong second quarter, but rising memory-chip costs and delayed hospital purchases could test margins.
View source ↗ - Newszacks.com·63d ago·Neutral
OMCL Falls 20.1% in a Month as Booking and Margin Risks Build Omnicell's 20.1% monthly slide reflects booking uncertainty, margin pressure and refresh-cycle risks despite a higher 2026 profit outlook.
View source ↗
Earnings
Thu, Oct 29(in 2 weeks)
Consensus estimate $0.42 per share
Typical surprise +45.2% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Jul 30$0.94 vs $0.47beat
- Tue, Apr 28$0.55 vs $0.33beat
- Thu, Feb 5$0.40 vs $0.47miss
- Thu, Oct 30$0.51 vs $0.36beat
- Thu, Jul 31$0.45 vs $0.31beat
- Tue, May 6$0.26 vs $0.16beat
Estimates and results for OMCL via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by OMCL officers and directors.
- Bought
- $350k
- Sold
- $3.7m
1 trade
13 trades
- Njoku Nnamdisold
- Lipps Randall Asold
- Njoku Nnamdisold
- Manley Corey Jsold
- Manley Corey Jsold
- Manley Corey Jsold
- Manley Corey Jsold
- Manley Corey Jsold
86 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Sara Jacobshouse · CA53 · disclosed May 28, 2021 (49d later)Sell$50,001 - $100,000
- Thomas Roland Tillissenate · NC · disclosed Feb 26, 2015 (13d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.